Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan vs Melphalan and Bortezomib in Older Multiple Myeloma Patients
NCT01453088Phase 2Terminated
- Sponsor
- Hackensack Meridian Health
- Start
- Jun 2010
- Primary completion
- May 2022
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by Hackensack Meridian Health. Started Jun 2010; status: terminated.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01453088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01453088.